SecProbe.io

CORRESP
1
filename1.htm

February 26, 2018

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

    Attn:
    Irene Paik

    Office of Healthcare & Insurance

 Re: Oncobiologics, Inc.

Registration Statement on Form S-3

Filed February 15, 2018

File No. 333-223063

Acceleration Request

    Requested Date:
    Wednesday, February 28, 2018

    Requested Time:
    4:00 P.M. Eastern Time

Ladies and Gentlemen:

In accordance with
Rule 461 under the Securities Act of 1933, as amended, Oncobiologics, Inc. (the “Registrant”) hereby
requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action
to cause the above-referenced Registration Statement on Form S-3 (File No. 333-223063) to become effective on February 28, 2018,
at 4:00 P.M., Eastern Time, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally
request via telephone call to the staff of the Commission (the “Staff”). The Registrant hereby authorizes
each of Yvan-Claude Pierre and Marianne Sarrazin of Cooley LLP, counsel to the Registrant, to make such request on its behalf.

In connection with
this request, the Registrant acknowledges that:

 · should the Commission or the Staff, acting
pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with
respect to the filing;

 · the action of the Commission or the Staff,
acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility
for the adequacy and accuracy of the disclosure in the filing; and

 · the Registrant may not assert Staff comments
and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal
securities laws of the United States.

    7 Clarke Drive, Cranbury, NJ  08512

    (609) 619-3990

    Very truly yours,

    Oncobiologics, Inc.

    By:
         /s/ Lawrence A. Kenyon

    Lawrence A. Kenyon

    Chief Financial Officer

 cc: Pankaj Mohan, Ph.D. Oncobiologics, Inc.

   Yvan-Claude Pierre, Cooley LLP

   Marianne Sarrazin, Cooley LLP